Obesity Therapy
C75 is a potential obesity drug that acts on CPT I activity and palmitate oxidation
Published in Obesity and Diabetes Week, May 29th, 2006
"C75 is a potential drug for the treatment of obesity. It was first identified as a competitive, irreversible inhibitor of fatty acid synthase (FAS). It has also been described as a malonyl-CoA analogue that antagonizes the allosteric inhibitory effect of malonyl-CoA oil carnitine palmitoyltransferase I (CPT I), the main regulatory enzyme involved in fatty acid oxidation. On the basis of MALDI-TOF analysis, we now provide evidence that C75 can be transformed to its C75-CoA derivative," researchers in Spain report.
A. Bentebibel and...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Diabetes Complications
Obesity common among type 2 diabetes in secondary care - Diabetes Pathogenesis
alpha2 -Heremans-Schmid glycoprotein is linked to insulin resistance and fat accumulation - Diet & Nutrition
Cereal fiber improves whole-body insulin sensitivity in overweight and obese women - Gastric Bypass
Roux-en-Y gastric bypass effectively treated comorbid conditions in super-obese - Obesity & Coronary Artery Disease
Obese coronary artery disease patients undergoing MPS were at lower risk of cardiac death - Adipose Tissue
Immunoglobulins produced by adipose tissue cells may alter metabolism and cytokine production - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
